Homepage | Spatially targeted eradication of antimicrobial-resistant bacteria

What is the TARGET-THERAPY Project?

Informations les plus recherchées

L'info de la semaine

18 January 2023

Convention - partenariat

EVOSENS Company in TARGET-THERAPY project

EVOSENS participates in TARGET-THERAPY project by providing light set-up solutions for medical – antimicrobial – purposes Read more...

Key data

74%

Project progression

From April 1, 2021 to December 31, 2025 (57 months in total)

3

Research sites

- Univ Brest (FR)

- Univ Reims (FR)

- Univ Siegen (DE)

15

People

- Researchers

- Postdocs

- PhD students

731 108

Euros

Funded by:

- ANR (FR)

- BMBF (DE)

2nd French-German call for projects on antimicrobial resistance 2020 “One Health: AMR in environmental reservoirs and colonizing antibiotic resistant bacteria”

The specific objective of this project is to significantly improve the treatment of infections with the WHO priority-1 pathogen P. aeruginosa, which is one of the most dangerous key multi-drug resistant bacteria, inside biofilms in the lungs.

Affiliated institutions

Publication des premiers résultats de l'appel à projets générique 2018 | ANR